Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05788016 · ClinicalTrials.gov registry record · NA
Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
A NA study of Chronic Pain and Arthritis Knee, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05788016: Recruiting NA study of Chronic Pain and Arthritis Knee, sponsored by University of Alabama at Birmingham.
NCT05788016 is a NA study of Chronic Pain and Arthritis Knee that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05788016, a NA study of Chronic Pain and Arthritis Knee, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Primary Outcome
Mixed-methods assessment of the intervention by participants. Participants will provide qualitative feedback at multiple points during and after the intervention, and will quantitatively rate satisfaction at the end of the study. These results will be analyzed jointly to determine acceptability.
Conditions Studied
Interventions
- BEHAVIORAL opioid taper
Study Locations (1)
Alabama
- UAB Hospital-Highlands - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What NCT05788016 shows while recruiting
NCT05788016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which opioid taper is the first listed.
NCT05788016 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05788016 about?
NCT05788016 is a clinical study titled "Developing an Opioid Taper Intervention Before Total Joint Arthroplasty". The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to pa...
What is the current status of trial NCT05788016?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2024-01-10. Estimated completion is 2026-09-01.
What conditions does trial NCT05788016 study?
This clinical trial studies the following conditions: Chronic Pain, Arthritis Knee, Arthritis Hip.
What interventions are being tested in trial NCT05788016?
The interventions under investigation include: opioid taper (BEHAVIORAL).
Who is sponsoring clinical trial NCT05788016?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05788016 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05788016's enrollment target sits among peer trials
45 206th of 301 higher than 95 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
RECRUITING · NA
-
Local Cerebral Oxygenation in Chronic Pain Patients Utilizing Spinal Cord Stimulation
RECRUITING · NA
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma
RECRUITING · NA
-
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
RECRUITING · NA
-
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI